Traditionally, when we think of a country’s growth, we imagine roads, bridges, and power plants. In recent years, healthcare technology has rightly earned a place alongside these pillars, but given today’s challenges, it deserves even greater urgency and investment.
The pandemic highlighted the fragility of healthcare systems but also showcased how quickly innovation could make a difference. Startups stepped in with rapid testing solutions and remote patient monitoring tools, addressing urgent gaps where traditional systems were struggling.
Fast forward to today, the healthcare sector has become even more advanced. With technologies like artificial intelligence (AI) playing a key role, the sector is flourishing. And at the heart of this transformation are the startups, young companies driven by boundless ambition and limited resources, bringing bold ideas to life.
And it’s only natural to ask if there’s a role for governments in helping them grow, and more and more, the answer feels like a clear yes.
The New Backbone of National Growth
Let’s start with the numbers. A 2023 report from NITI Aayog highlighted that India’s digital health market will reach $37 billion by 2030, growing at an annual rate of 25%. Another analysis suggests that the global digital healthcare market is expected to surpass $660 billion by 2025.
These aren’t just impressive figures; they signal a profound shift in healthcare delivery, moving from hospitals to homes, from treatment to prevention, and from human care to tech-enabled solutions.
But making that shift is no small feat. Unlike fintech or edtech, healthcare startups face higher barriers, such as complex regulations, longer timelines for market entry, and the burden of proving their products’ clinical efficacy.
For instance, the average time for a new pharmaceutical product to progress from discovery to regulatory approval is typically around 7 years, with clinical development alone often taking 5 to 7 years. This lengthy process is due to rigorous testing, regulatory requirements, and the complexity of clinical trials in the healthcare sector.
That’s where government support, such as financial backing, policy guidance, and regulatory facilitation, becomes crucial.
Public Benefit, Private Risk
When governments invest in infrastructure, they prioritize long-term public goods like job creation, economic growth, and crisis resilience, much like healthcare startups that leverage technology to address systemic challenges.
Indian innovators such as Practo, Apollo Telehealth, and Tattvan E-Clinics extend telemedicine access to rural areas, bridging gaps between urban specialists and remote patients, while DigiQure and PharmEasy deliver affordable consultations and medicines to underserved communities. Startups like HealthPlix empower doctors with AI-driven tools for remote monitoring and streamlined care, reducing hospital burdens and enabling early disease detection through data analytics.
These efforts mirror the societal benefits of infrastructure investment—equitable access, efficiency, and resilience, demonstrating how strategic technology and public-sector initiatives together strengthen communities and safeguard public health.
But here's the catch: most healthcare startups are either bootstrapped or reliant on venture capital that demands quick returns. This pressure can force them to cut corners or rush to market before their products are fully validated.
Government intervention through grants, tax incentives, or public procurement programs can provide these startups with the time and resources they need to refine their products and ensure they’re having the desired impact on public health.
Positive Steps Already Underway
To be fair, governments have already made notable strides. In India, initiatives like the Ayushman Bharat Digital Mission (ABDM), the BIRAC healthcare innovation grants, and the SAMRIDH Blended Finance Facility are creating important pathways for startup engagement. The launch of the National Digital Health Mission has further opened doors for startups to innovate within a supportive regulatory framework.
Similarly, globally, programs like the NHS Test Beds initiative in the UK and BARDA DRIVe in the U.S. have shown how structured public-private partnerships can accelerate innovation.
These programs provide a strong foundation. The opportunity now is to build on this momentum.
The Role of Policy and Procurement
Government support shouldn’t stop at funding. Public institutions can become early adopters of healthcare solutions and products. Public health systems can set up pilot programs, create innovation procurement quotas, and offer startups real-world testing environments
Additionally, regulatory bodies can create streamlined pathways for startups to navigate compliance. Initiatives like regulatory sandboxes, expedited clinical validation processes, and data interoperability standards can make the journey less bureaucratic and more agile, allowing startups to innovate faster without compromising on safety.
The Final Thought
Healthcare startups are at the leading edge of the next great advance in global healthcare. They have the ideas, the energy, and the ambition—but to truly remake healthcare delivery, they need more robust ecosystems around them.
Governments should ask: are we doing enough to support these innovators who are answering some of our most pressing public health needs? And for start-ups: how can they direct their innovations not only toward market success, but also toward wider public benefit?
By providing more assistance through financing, easier regulations, and collaborations, governments can unlock a future where healthcare is more accessible, proactive, and resilient.
In turn, startups should remain committed to finding a balance between swift growth and the essential duty of maintaining safety and effectiveness. Collectively, they can turn possibilities into realities, building a healthcare system that works better for all—a future truly worth investing in.
Edited by Harshajit Sarmah
